[424B5] Scienture Holdings, Inc. Prospectus Supplement (Debt Securities)
Scienture Holdings filed an amended prospectus supplement to register the offer and sale of up to $9,592,009 of common stock, from time to time through Maxim Group LLC under its at-the-market program pursuant to Form S-3.
The amendment increases the amount eligible to be sold under General Instruction I.B.6, which limits primary offerings to no more than one-third of public float while it remains below $75,000,000. The company has sold approximately $13,252,250 during the prior 12 months, leaving $9,592,009 available under the Sales Agreement.
Shares trade on Nasdaq as SCNX; the last reported price was $2.60 per share on October 23, 2025. Shares outstanding were 34,474,230 as of October 23, 2025, and the aggregate market value of non-affiliate holdings used for the I.B.6 calculation was approximately $68,601,377.
Scienture Holdings ha depositato un supplemento di prospetto modificato per registrare l'offerta e la vendita di fino a $9,592,009 di azioni ordinarie, di volta in volta tramite Maxim Group LLC nell'ambito del suo programma at-the-market ai sensi della Form S-3.
L'emendamento aumenta l'importo idoneo per la vendita ai sensi della General Instruction I.B.6, la quale limita le offerte primarie a non più di un terzo del flottante pubblico finché rimane al di sotto di $75,000,000. L'azienda ha venduto circa $13,252,250 nei 12 mesi precedenti, lasciando $9,592,009 disponibile ai sensi dell'Sales Agreement.
Le azioni sono negoziate al Nasdaq con ticker SCNX; l'ultimo prezzo riportato è stato di $2.60 per azione il 23 ottobre 2025. Le azioni in circolazione ammontavano a 34,474,230 al 23 ottobre 2025, e il valore di mercato aggregato delle partecipazioni non appartenenti agli affiliati utilizzato nel calcolo I.B.6 era di circa $68,601,377.
Scienture Holdings presentó un suplemento de folleto enmendado para registrar la oferta y venta de hasta $9,592,009 de acciones comunes, de vez en cuando a través de Maxim Group LLC bajo su programa at-the-market conforme a la Form S-3.
La enmienda aumenta la cantidad elegible para venderse bajo la Instrucción General I.B.6, que limita las ofertas primarias a no más de un tercio del flotante público mientras permanezca por debajo de $75,000,000. La empresa ha vendido aproximadamente $13,252,250 durante los 12 meses previos, dejando $9,592,009 disponible bajo el Acuerdo de Ventas.
Las acciones cotizan en Nasdaq como SCNX; el último precio reportado fue de $2.60 por acción el 23 de octubre de 2025. Las acciones en circulación eran de 34,474,230 a 23 de octubre de 2025, y el valor de mercado agregado de las participaciones no afiliadas utilizado para el cálculo I.B.6 era de aproximadamente $68,601,377.
Scienture Holdings은 S-3 양식에 따른 시장가 매매 프로그램 하에 Maxim Group LLC를 통해 때때로 발행 및 매각될 최대 $9,592,009의 보통주를 등록하기 위한 수정된 증권설명서 보충서를 제출했습니다.
이 개정은 I.B.6 일반 지침에 따라 매각 가능 금액을 증가시키며, 이는 공공 유동성의 1/3을 넘지 않는 한도에서, 75,000,000 달러 미만일 때 적용됩니다. 회사는 지난 12개월 동안 대략 $13,252,250를 매도했으며, Sales Agreement 하에 $9,592,009이 남아 있습니다.
주식은 Nasdaq에서 SCNX로 거래되며, 마지막 보고된 가격은 2025년 10월 23일에 주당 $2.60이었습니다. 발행 주식 수는 2025년 10월 23일 기준 34,474,230주였고, I.B.6 계산에 사용된 비계열 보유의 총 시장 가치는 대략 $68,601,377였습니다.
Scienture Holdings a déposé un supplément de prospectus modifié afin d'enregistrer l'offre et la vente d'un maximum de $9,592,009 actions ordinaires, de temps à autre par l'intermédiaire de Maxim Group LLC dans le cadre de son programme de place de marché (at-the-market) conformément au formulaire S-3.
L'amendement augmente le montant éligible à être vendu en vertu de l'instruction générale I.B.6, qui limite les offres primaires à pas plus d'un tiers du flottant public tant que celui-ci reste en dessous de 75 000 000 $. L'entreprise a vendu environ $13,252,250 au cours des 12 mois précédents, laissant $9,592,009 disponible en vertu de l'Accord de Vente.
Les actions se négocient au Nasdaq sous le code SCNX; le dernier prix enregistré était de $2.60 par action le 23 octobre 2025. Les actions en circulation étaient de 34,474,230 au 23 octobre 2025, et la valeur marchande totale des avoirs non affiliés utilisés pour le calcul I.B.6 était d'environ $68,601,377.
Scienture Holdings hat einen geänderten Prospektenhinterlegungsentwurf eingereicht, um das Angebot und den Verkauf von bis zu $9,592,009 Stammaktien zu registrieren, von Zeit zu Zeit über Maxim Group LLC im Rahmen ihres At-the-Market-Programms gemäß Form S-3.
Die Änderung erhöht den Betrag, der gemäß Allgemeine Anweisung I.B.6 verkauft werden kann, die Primärangebote auf nicht mehr als ein Drittel des öffentlichen Streuv zu begrenzen, solange es unter $75,000,000 bleibt. Das Unternehmen hat in den vergangenen 12 Monaten ca. $13,252,250 verkauft und verbleibend $9,592,009 unter dem Sales Agreement.
Die Aktien werden an der Nasdaq unter dem Ticker SCNX gehandelt; der zuletzt berichtete Preis betrug am 23. Oktober 2025 $2.60 pro Aktie. Die ausstehenden Aktien beliefen sich am 23. Oktober 2025 auf 34,474,230 und der aggregierte Marktwert der Beteiligungen von Nicht-Affiliates, der für die I.B.6-Berechnung verwendet wurde, belief sich auf ca. $68,601,377.
Scienture Holdings قدمت ملحق نشرة إصدار معدل لتسجيل العرض وبيع ما يصل إلى $9,592,009 من الأسهم العادية، من حين لآخر من خلال Maxim Group LLC ضمن برنامجها في السوق وفقاً للنموذج S-3.
يزيد التعديل المبلغ المؤهل للبيع وفقاً للتعليمات العامة I.B.6، التي تقتصر العروض الأولية على ما لا يزيد عن ثلث التدفق العام بينما يظل دون 75,000,000 دولار. لقد باعت الشركة نحو $13,252,250 خلال الـ12 شهراً الماضية، مما يترك $9,592,009 متاحاً بموجب اتفاق المبيعات.
تتداول الأسهم في ناسداك تحت الرمز SCNX; كان آخر سعر مُبلَّغ عنه هو $2.60 للسهم في 23 أكتوبر 2025. كانت الأسهم القائمة حتى 23 أكتوبر 2025 تبلغ 34,474,230، وكان القيمة السوقية الإجمالية لحيازات غير المرتبطة بالأطراف التابعة المستخدمة في حساب I.B.6 حوالي $68,601,377.
- None.
- None.
Scienture Holdings ha depositato un supplemento di prospetto modificato per registrare l'offerta e la vendita di fino a $9,592,009 di azioni ordinarie, di volta in volta tramite Maxim Group LLC nell'ambito del suo programma at-the-market ai sensi della Form S-3.
L'emendamento aumenta l'importo idoneo per la vendita ai sensi della General Instruction I.B.6, la quale limita le offerte primarie a non più di un terzo del flottante pubblico finché rimane al di sotto di $75,000,000. L'azienda ha venduto circa $13,252,250 nei 12 mesi precedenti, lasciando $9,592,009 disponibile ai sensi dell'Sales Agreement.
Le azioni sono negoziate al Nasdaq con ticker SCNX; l'ultimo prezzo riportato è stato di $2.60 per azione il 23 ottobre 2025. Le azioni in circolazione ammontavano a 34,474,230 al 23 ottobre 2025, e il valore di mercato aggregato delle partecipazioni non appartenenti agli affiliati utilizzato nel calcolo I.B.6 era di circa $68,601,377.
Scienture Holdings presentó un suplemento de folleto enmendado para registrar la oferta y venta de hasta $9,592,009 de acciones comunes, de vez en cuando a través de Maxim Group LLC bajo su programa at-the-market conforme a la Form S-3.
La enmienda aumenta la cantidad elegible para venderse bajo la Instrucción General I.B.6, que limita las ofertas primarias a no más de un tercio del flotante público mientras permanezca por debajo de $75,000,000. La empresa ha vendido aproximadamente $13,252,250 durante los 12 meses previos, dejando $9,592,009 disponible bajo el Acuerdo de Ventas.
Las acciones cotizan en Nasdaq como SCNX; el último precio reportado fue de $2.60 por acción el 23 de octubre de 2025. Las acciones en circulación eran de 34,474,230 a 23 de octubre de 2025, y el valor de mercado agregado de las participaciones no afiliadas utilizado para el cálculo I.B.6 era de aproximadamente $68,601,377.
Scienture Holdings은 S-3 양식에 따른 시장가 매매 프로그램 하에 Maxim Group LLC를 통해 때때로 발행 및 매각될 최대 $9,592,009의 보통주를 등록하기 위한 수정된 증권설명서 보충서를 제출했습니다.
이 개정은 I.B.6 일반 지침에 따라 매각 가능 금액을 증가시키며, 이는 공공 유동성의 1/3을 넘지 않는 한도에서, 75,000,000 달러 미만일 때 적용됩니다. 회사는 지난 12개월 동안 대략 $13,252,250를 매도했으며, Sales Agreement 하에 $9,592,009이 남아 있습니다.
주식은 Nasdaq에서 SCNX로 거래되며, 마지막 보고된 가격은 2025년 10월 23일에 주당 $2.60이었습니다. 발행 주식 수는 2025년 10월 23일 기준 34,474,230주였고, I.B.6 계산에 사용된 비계열 보유의 총 시장 가치는 대략 $68,601,377였습니다.
Scienture Holdings a déposé un supplément de prospectus modifié afin d'enregistrer l'offre et la vente d'un maximum de $9,592,009 actions ordinaires, de temps à autre par l'intermédiaire de Maxim Group LLC dans le cadre de son programme de place de marché (at-the-market) conformément au formulaire S-3.
L'amendement augmente le montant éligible à être vendu en vertu de l'instruction générale I.B.6, qui limite les offres primaires à pas plus d'un tiers du flottant public tant que celui-ci reste en dessous de 75 000 000 $. L'entreprise a vendu environ $13,252,250 au cours des 12 mois précédents, laissant $9,592,009 disponible en vertu de l'Accord de Vente.
Les actions se négocient au Nasdaq sous le code SCNX; le dernier prix enregistré était de $2.60 par action le 23 octobre 2025. Les actions en circulation étaient de 34,474,230 au 23 octobre 2025, et la valeur marchande totale des avoirs non affiliés utilisés pour le calcul I.B.6 était d'environ $68,601,377.
Scienture Holdings hat einen geänderten Prospektenhinterlegungsentwurf eingereicht, um das Angebot und den Verkauf von bis zu $9,592,009 Stammaktien zu registrieren, von Zeit zu Zeit über Maxim Group LLC im Rahmen ihres At-the-Market-Programms gemäß Form S-3.
Die Änderung erhöht den Betrag, der gemäß Allgemeine Anweisung I.B.6 verkauft werden kann, die Primärangebote auf nicht mehr als ein Drittel des öffentlichen Streuv zu begrenzen, solange es unter $75,000,000 bleibt. Das Unternehmen hat in den vergangenen 12 Monaten ca. $13,252,250 verkauft und verbleibend $9,592,009 unter dem Sales Agreement.
Die Aktien werden an der Nasdaq unter dem Ticker SCNX gehandelt; der zuletzt berichtete Preis betrug am 23. Oktober 2025 $2.60 pro Aktie. Die ausstehenden Aktien beliefen sich am 23. Oktober 2025 auf 34,474,230 und der aggregierte Marktwert der Beteiligungen von Nicht-Affiliates, der für die I.B.6-Berechnung verwendet wurde, belief sich auf ca. $68,601,377.
Scienture Holdings قدمت ملحق نشرة إصدار معدل لتسجيل العرض وبيع ما يصل إلى $9,592,009 من الأسهم العادية، من حين لآخر من خلال Maxim Group LLC ضمن برنامجها في السوق وفقاً للنموذج S-3.
يزيد التعديل المبلغ المؤهل للبيع وفقاً للتعليمات العامة I.B.6، التي تقتصر العروض الأولية على ما لا يزيد عن ثلث التدفق العام بينما يظل دون 75,000,000 دولار. لقد باعت الشركة نحو $13,252,250 خلال الـ12 شهراً الماضية، مما يترك $9,592,009 متاحاً بموجب اتفاق المبيعات.
تتداول الأسهم في ناسداك تحت الرمز SCNX; كان آخر سعر مُبلَّغ عنه هو $2.60 للسهم في 23 أكتوبر 2025. كانت الأسهم القائمة حتى 23 أكتوبر 2025 تبلغ 34,474,230، وكان القيمة السوقية الإجمالية لحيازات غير المرتبطة بالأطراف التابعة المستخدمة في حساب I.B.6 حوالي $68,601,377.
Scienture Holdings 提交了经修订的招股说明书增补，以注册最高至 $9,592,009 股普通股的要约与销售，该销售将不时通过 Maxim Group LLC 在其市场即进即售计划下，依据表格 S-3 进行。
该修订提高了根据一般指令 I.B.6 可出售的金额，该指令在市值未超过 75,000,000 美元时，将初级发行限制为不多于公开浮动的三分之一。公司在前12个月大约已售出 $13,252,250，在销售协议下还剩 $9,592,009 可用。
股票在纳斯达克交易，代码为 SCNX；最近一次报道的价格是在 2025 年 10 月 23 日为每股 $2.60。截至 2025 年 10 月 23 日，流通在外股数为 34,474,230，用于 I.B.6 计算的非关联股东持股的总市值约为 $68,601,377。
Filed pursuant to Rule 424(b)(5)
Registration No. 333-289198
AMENDMENT NO. 1 DATED OCTOBER 24, 2025
To Prospectus Supplement dated September 19, 2025
(To Prospectus dated August 8, 2025)
$9,592,009
Scienture Holdings, Inc.
Common Stock
This prospectus supplement (“Prospectus Supplement No. 1”) amends and supplements the information in the prospectus supplement dated September 19, 2025, filed with the Securities and Exchange Commission as part of our registration statement on Form S-3, File No. 333-289198 (the “Prospectus Supplement”). This Amendment No. 1 should be read in conjunction with the Prospectus Supplement and the accompanying prospectus dated August 8, 2025 (the “Prospectus”), each of which are to be delivered with this Amendment No. 1, as well as any of our SEC filings which amend and update this Prospectus Supplement.
We are filing this Prospectus Supplement No. 1 solely to increase the amount of shares of our common stock, par value $0.00001 per share (the “Common Stock”), that we are eligible to sell under General Instruction I.B.6 of Form S-3 and pursuant to the equity distribution agreement (the “Sales Agreement”) with Maxim Group LLC (the “Sales Agent”), dated September 19, 2025, to an aggregate offering price of up to $9,592,009. This Prospectus Supplement No. 1 is registering the offer and sale of up to $9,592,009 in gross proceeds of our shares of Common Stock from time to time through the Sales Agent, acting as agent. This Prospectus Supplement No. 1 is not complete without and may only be delivered or utilized in connection with the Prospectus Supplement, the Prospectus, and any future amendments or supplements thereto.
Our shares of Common Stock are traded on the Capital Market tier of The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “SCNX”. On October 23, 2025, the last reported per share sale price of our shares of Common Stock on Nasdaq was $2.60 per share.
The aggregate market value of the outstanding shares of our Common Stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 was approximately $68,601,377, which was calculated based on 34,474,230 shares of Common Stock outstanding as of October 23, 2025, of which 8,089,085 shares of Common Stock were held by affiliates, and a price of $2.60 per share, which was the closing price of our shares of Common Stock on Nasdaq on October 23, 2025. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75,000,000. We have sold approximately $13,252,250 in gross proceeds of securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this Prospectus Supplement No. 1, and therefore $9,592,009 remains available to be sold pursuant to this Prospectus Supplement No. 1 and the Sales Agreement.
Investing in our securities involves a high degree of risk. You should read this prospectus supplement dated October 24, 2025 and the accompanying prospectus carefully before you make your investment decision.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
MAXIM GROUP LLC
The date of this Prospectus Supplement No. 1 is October 24, 2025.
FAQ
What is SCNX registering in this amendment?
What rule limits the size of SCNX’s ATM sales?
How much has SCNX sold in the last 12 months under I.B.6?
How much capacity remains available to sell?
What is SCNX’s public float used for the I.B.6 calculation?
What are SCNX’s shares outstanding and last price referenced?
Where is SCNX listed and what is the ticker?
